




RealRate

PHARMACEUTICAL 2018

NightHawk Biosciences Inc.
Rank 217 of 349



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2018

NightHawk Biosciences Inc. Rank 217 of 349



The relative strengths and weaknesses of NightHawk Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NightHawk Biosciences Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 62% points. The greatest weakness of NightHawk Biosciences Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 58% points.

The company's Economic Capital Ratio, given in the ranking table, is -249%, being 29% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	11,745
Cost of Goods Sold	0
Intangible Assets	2,189
Liabilities, Current	10,336
Liabilities, Non-Current	161
Other Assets	5,968
Other Compr. Net Income	474
Other Expenses	-585
Other Liabilities	3,912
Other Net Income	123
Property and Equipment	287
Research and Development	8,268
Revenues	1,520
Selling, General and Administrative Expense	6,371

Output Variable	Value in 1000 USD
Assets	20,189
Liabilities	14,409
Expenses	14,053
Stockholders Equity	5,781
Net Income	-12,410
Comprehensive Net Income	-12,173
Economic Capital Ratio	-249%

